A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs AZD 5634 (Primary) ; AZD 5634 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 10 Nov 2016 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.